HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 05, May 2018 – Dental health - The root to good health       » Drugs to watch 2018       » Dragonfly-inspired nano coating kills bacteria upon contact       » New compound improves stroke recovery in monkeys and mice       » Cancer stem cell therapy breakthrough       » Draft genome of tea plant sequenced      
INSIDE INDUSTRY
Drugs to watch 2018
12 new drugs are forecast to enter the market in 2018 and achieve blockbuster sales of USD1 billion or more by 2022

As the drug-pricing debate continues in the U.S., 2017 saw a record of 46 new drug approvals by the Food and Drug Administration (FDA), the highest total in more than two decades. Of these approved drugs, 17 (37 per cent) were approved with Breakthrough Therapy designation, a designation created in 2012 to accelerate the development of products that showed substantial improvement over existing therapies for serious and life-threatening diseases.

The approval of cancer immunotherapies—Novartis’ Kymriah (tisagenlecleucel) and Gilead’s Yescarta (axicabtagene ciloleucel) chimeric antigen receptor T cell (CAR-T) therapies—grabbed headlines in 2017 because of their ability to revolutionize the treatment of the disease. These therapies, a form of gene therapy, represent a major breakthrough for the development of personalized medicine and lay the groundwork for further advances in this field.

More than half of the drugs in 2018 have been granted Priority Review, Breakthrough Therapy or Fast Track designations. Five drugs on the list are first-in-class and four are for orphan diseases.

In stark contrast to 2017, where more than half of the drugs on the blockbuster list were cancer treatments, only one blockbuster expected to launch in 2018 is for cancer (Erleada [apalutamide]).

Despite political and regulatory uncertainties in the U.S. and EU markets, the pace of pharmaceutical innovation continues to accelerate. 2018 is on track to see many new and potentially game-changing drugs come to market, benefiting the lives of millions of patients around the world.

A few additional therapies could enter the market in 2018 that are worth watching, especially if they receive accelerated approval.

Juno Therapeutics’ CAR T-cell therapy, lisocabtagene maraleucel, is expected to be filed for diffuse large B-cell lymphoma in the second half of 2018 and has 2022 sales forecasts of USD2.221 billion.

Alexion’s next-generation Soliris treatment, ravulizumab, for paroxysmal nocturnal hemoglobinuria, is expected to file for approval in the third quarter of 2018. This drug is forecast to generate USD2.199 billion of sales by 2022.

Click here for the complete issue.

NEWS CRUNCH  
news Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Oncology / Biotech landscape in APAC
July:
Water management / Vaccination
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy